<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Boston Criteria for cerebral amyloid angiopathy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Boston Criteria for cerebral amyloid angiopathy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Boston Criteria for cerebral amyloid angiopathy</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33.3%"></colgroup> <tbody> <tr> <td class="subtitle1">Boston criteria for sporadic CAA version 2.0, 2022<sup>[1]</sup></td> <td class="subtitle1">Modified Boston criteria version 1.5, 2010<sup>[2]</sup></td> <td class="subtitle1">Boston criteria, 2001<sup>[3]</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="3">Definite CAA</td> </tr> <tr> <td class="indent1"><strong>Full postmortem examination demonstrating:</strong> <ul class="decimal_heading"> <li>Spontaneous ICH, TFNE, cSAH, cognitive impairment</li> <li>Severe CAA with vasculopathy</li> <li>Absence of other diagnostic lesion</li> </ul> </td> <td> <strong>Full postmortem examination demonstrating:</strong> <ul class="decimal_heading"> <li>Lobar, cortical, or cortico-subcortical hemorrhage</li> <li>Severe CAA with vasculopathy</li> <li>Absence of other diagnostic lesion</li> </ul> </td> <td> <strong>Full postmortem examination demonstrating:</strong> <ul class="decimal_heading"> <li>Lobar, cortical, or cortico-subcortical hemorrhage</li> <li>Severe CAA with vasculopathy</li> <li>Absence of other diagnostic lesion</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">Probable CAA with supporting pathology</td> </tr> <tr> <td class="indent1"> <strong>Clinical data and pathologic tissue (evacuated hematoma or cortical biopsy):</strong> <ul class="decimal_heading"> <li>Presentation with spontaneous ICH, TFNE, cSAH, or cognitive impairment</li> <li>Some degree of CAA in specimen</li> <li>Absence of other diagnostic lesion</li> </ul> </td> <td><strong>Clinical data and pathologic tissue (evacuated hematoma or cortical biopsy):</strong> <ul class="decimal_heading"> <li>Lobar, cortical, or cortico-subcortical hemorrhage</li> <li>Some degree of CAA in specimen</li> <li>Absence of other diagnostic lesion</li> </ul> </td> <td><strong>Clinical data and pathologic tissue (evacuated hematoma or cortical biopsy):</strong> <ul class="decimal_heading"> <li>Lobar, cortical, or cortico-subcortical hemorrhage</li> <li>Some degree of CAA in specimen</li> <li>Absence of other diagnostic lesion</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">Probable CAA</td> </tr> <tr> <td class="indent1"><strong>Clinical data and MRI demonstrating:</strong> <ul class="decimal_heading"> <li>Age ≥50 years</li> <li><strong>Plus either:</strong> <ul> <li>Presentation with spontaneous ICH, TFNE, or cognitive impairment</li> <li>Two or more lobar hemorrhagic lesions on T2*-weighted imaging (eg, ICH, CMB, cSS, cSAH)<sup>¶</sup></li> <li>Absence of other cause of hemorrhage<sup>Δ</sup> <ul class="none"> <li><strong>or</strong></li> </ul> </li> <li>One lobar hemorrhagic lesion on T2*-weighted imaging (eg, ICH, CMB, cSS, cSAH)<sup>◊</sup></li> <li>One white matter feature (eg, &gt;20 perivascular spaces in centrum semiovale or WMH in a multispot pattern)</li> <li>Absence of any deep hemorrhagic lesions on T2*-weighted imaging (eg, ICH, CMB)<sup>¶</sup></li> <li>Absence of other cause of hemorrhagic lesions<sup>Δ</sup></li> </ul> </li> </ul> </td> <td><strong>Clinical data and MRI demonstrating:</strong> <ul class="decimal_heading"> <li>Age ≥55 years</li> <li><strong>Plus either:</strong> <ul> <li>Multiple hemorrhages restricted to lobar, cortical, or cortico-subcortical regions (cerebellar hemorrhage allowed) <ul class="none"> <li><strong>or</strong></li> </ul> </li> <li>Single lobar, cortical, or cortico-subcortical hemorrhage and focal<sup>§</sup> or disseminated<sup>¥</sup> superficial siderosis</li> </ul> </li> <li>Absence of other cause of hemorrhage or superficial siderosis</li> </ul> </td> <td><strong>Clinical data and MRI demonstrating:</strong> <ul class="decimal_heading"> <li>Age ≥55 years</li> <li>Multiple hemorrhages restricted to lobar, cortical, or cortico-subcortical regions (cerebellar hemorrhage allowed)</li> <li>Absence of other cause of hemorrhage<sup>◊</sup></li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">Possible CAA</td> </tr> <tr> <td class="indent1"><strong>Clinical data and MRI demonstrating:</strong> <ul class="decimal_heading"> <li>Age ≥50 years</li> <li><strong>Plus either:</strong> <ul> <li>Presentation with spontaneous ICH, TFNE, cSAH, or cognitive impairment</li> <li>One lobar hemorrhagic lesion on T2*-weighted imaging (eg, ICH, CMB, cSS, cSAH)<sup>¶</sup></li> <li>Absence of other cause of hemorrhage<sup>Δ</sup> <ul class="none"> <li><strong>or</strong></li> </ul> </li> <li>One white matter feature (eg, &gt;20 perivascular spaces in centrum semiovale or WMH in a multispot pattern)</li> <li>Absence of any deep hemorrhagic lesions on T2*-weighted imaging (eg, ICH, CMB)<sup>¶</sup></li> <li>Absence of other cause of hemorrhagic lesions<sup>Δ</sup></li> </ul> </li> </ul> </td> <td><strong>Clinical data and MRI demonstrating:</strong> <ul class="decimal_heading"> <li>Age ≥55 years</li> <li><strong>Plus either:</strong> <ul> <li>Single lobar, cortical, or cortico-subcortical hemorrhage <ul class="none"> <li><strong>or</strong></li> </ul> </li> <li>Focal<sup>§</sup> or disseminated<sup>¥</sup> superficial siderosis</li> </ul> </li> <li>Absence of other cause of hemorrhage or superficial siderosis</li> </ul> </td> <td><strong>Clinical data and MRI demonstrating:</strong> <ul class="decimal_heading"> <li>Age ≥55 years</li> <li>Single lobar, cortical, or cortico-subcortical hemorrhage</li> <li>Absence of other cause of hemorrhage<sup>◊</sup></li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">The Boston criteria incorporate clinical, radiologic, and pathologic data to provide diagnostic certainty for patients with suspected CAA. Successive iterations of these criteria reflect the evolving understanding of these diagnostic features. Refer to UpToDate topics for additional information on the diagnosis and evaluation of patients with suspected CAA.</div><div class="graphic_footnotes"><p>CAA: cerebral amyloid angiopathy;
	ICH: intracerebral hemorrhage;
	TFNE: transient focal neurologic event;
	cSAH: convexity subarachnoid hemorrhage;
	MRI: magnetic resonance imaging;
	cSS: cortical superficial siderosis;
	WMH: white matter hyperintensity.</p>
<p>¶ Hemorrhagic lesion in the cerebellum is not counted as either lobar or deep hemorrhagic lesion.</p>
<p>Δ Other causes of hemorrhagic lesion: antecedent head trauma, hemorrhagic transformation of an ischemic stroke, arteriovenous malformation, hemorrhagic tumor, and vasculitis. Other causes of cortical superficial siderosis and acute convexity subarachnoid hemorrhage should also be excluded.</p>
<p>◊ Other causes of intracerebral hemorrhage: excessive warfarin (INR &gt;3.0); antecedent head trauma or ischemic stroke; central nervous system tumor, vascular malformation, or vasculitis; and blood dyscrasia or coagulopathy. (INR &gt;3.0 or other nonspecific laboratory abnormalities permitted for diagnosis of possible CAA.)</p>
<p>§ Siderosis restricted to 3 or fewer sulci.</p>
	
	¥ Siderosis affecting at least 4 sulci.</div><div class="graphic_reference">References:
	<ol>
<li>Charidimou A, Boulouis G, Frosch MP, et al. The
		Boston criteria version 2.0 for cerebral amyloid angiopathy: A multicentre,
		retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol
		2022; 21:714.</li>
<li>Linn J, Halpin A, Demaerel P, et al. Prevalence
		of superficial siderosis in patients with cerebral amyloid angiopathy.
		Neurology 2010; 74:1346.</li>
<li>Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical
		diagnosis of cerebral amyloid angiopathy: Validation of the Boston criteria.
		Neurology 2001; 56:537.</li>
</ol></div><div id="graphicVersion">Graphic 139328 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
